<DOC>
	<DOCNO>NCT01386983</DOCNO>
	<brief_summary>This retrospective study aim assess clinical economic impact early initiation 5-alpha-reductase inhibitor ( 5ARI ) therapy patient enlarge prostate ( EP ) receive 5ARI monotherapy combination therapy alpha-blocker ( AB ) compare late initiation 5ARI therapy patient receive combination therapy . The Henry Ford Health System databases utilized study ( 2000-2008 ) .</brief_summary>
	<brief_title>Clinical Economic Outcomes Patients Utilizing Combination Therapy Enlarged Prostates : A Henry Ford Database Assessment</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Males age 50 year old medical claim EP prescription claim ( ) either 5ARI 5ARI AB ( provide within 180 day index date ) continuously eligible 3 month prior least 5 month index prescription date . Patients prostate bladder cancer prostaterelated surgical procedure within 5 month index date prescription claim finasteride indicative male pattern baldness ; AB monotherapy ; initiation 5ARI occur 180 day initiation AB</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Enlarged prostate , 5-alpha-reductase inhibitor , alpha-blocker , acute urinary retention , surgery , early , cost</keyword>
	<keyword>benign prostatic hyperplasia</keyword>
</DOC>